Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Plan Denosumab Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealth Plan of the Upper Ohio Valley, Inc.Policy N/A

    Denosumab Prior Authorization Policy

    Customize your policy alerts

    Sign up for all healthplanofupperohiovalley policy alerts

    Know when healthplanofupperohiovalley releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization, dosing limits, and clinical approval criteria for denosumab products used for osteoporosis, cancer-related bone conditions, systemic mastocytosis, and related indications. Requests require pharmacist review and apply to members receiving denosumab under the listed clinical circumstances.

    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyDenosumab Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit denosumab requests for prior authorization and pharmacist review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization
    Bildyos and EnobyPreferred products
    60 units/6 monthsOsteoporosis dosing
    120 units/4 weeksOncology dosing

    Coverage Criteria

    Universal Initial Approval Criteria

    Covered when ALL applicable criteria are met:

    ALL of the following

    • Requested product is Prolia, Bildyos, Boncresa, Bosaya, Conexxence (denosumab-bnht), Enoby, Jubbonti, Ospomyv (denosumab-dssb), Osvyrti, Ponlimsi (denosumab-adet), or Stoboclo (denosumab-bmwo).
    • Bildi yos and Enoby are preferred denosumab products; the member has a contraindication, intolerance, or failure of Bildyos and Enoby.
    • Member is at least 18 years of age.
    • Member supplements with 1,000 mg of calcium and at least 400 IU of vitamin D daily.
    • Member does not have an FDA-labeled contraindication to the requested agent, including hypocalcemia or known hypersensitivity.
    • For members with advanced kidney disease (eGFR <30 mL/min/1.73 m², including dialysis-dependent members), CKD-mineral and bone disorder is evaluated with intact parathyroid hormone, serum calcium, 25-hydroxy vitamin D, and 1,25-dihydroxy vitamin D before denosumab treatment decisions.
    • Pregnancy is ruled out before administration in biological females of child-bearing potential.
    • Requested therapy will not be used in combination with another denosumab product, a bisphosphonate, romosozumab, or a parathyroid hormone analog or related peptide.

    Osteoporosis in Men and Women

    Covered when ALL applicable criteria are met:

    ALL of the following

    • For a biological female, member is post-menopausal.
    • Member is at high risk for fracture.
    • ONE of the following

      • Documented osteoporosis with a DXA T-score ≤ -2.5 at the lumbar spine, femoral neck, total hip, or forearm at the 33% (one-third) radius site.
      • History of fragility fracture of the hip or spine, regardless of T-score.
      • ALL of the following

    Glucocorticoid-Induced Osteoporosis

    Covered when ALL applicable criteria are met:

    ALL of the following

    • Member is initiating or continuing systemic glucocorticoid therapy at a daily dosage equivalent to ≥2.5 mg of prednisone and is expected to remain on glucocorticoid therapy for at least 3 months.
    • Member is at increased risk for fracture.
    • ONE of the following

      • Documented treatment failure or ineffective response to a minimum 12-month trial of an oral or intravenous bisphosphonate, such as alendronate, risedronate, ibandronate, or zoledronic acid.
      • Documented contraindication or intolerance to both oral and intravenous bisphosphonates.

    Prostate Cancer — Increase Bone Mass

    Covered when ALL applicable criteria are met:

    ALL of the following

    • Member is receiving androgen deprivation therapy.
    • Member is at high risk for fracture.

    Breast Cancer — Increase Bone Mass

    Covered when the following criterion is met:

    Member is receiving adjuvant aromatase inhibitor therapy for breast cancer.

    Systemic Mastocytosis

    Covered when ALL applicable criteria are met:

    ALL of the following

    • Member has osteopenia or osteoporosis and coexisting bone pain.
    • ONE of the following

      • Denosumab is being used as second-line therapy because the member is not responding to bisphosphonate therapy.
      • Member is not a candidate for bisphosphonate therapy because of renal insufficiency.

    Indication-Specific Dosing

    The applicable dose and schedule must correspond to the requested indication:

    ONE applicable dosing pathway

    • Osteoporosis or systemic mastocytosis: 60 billable units every 6 months.
    • Giant cell tumor of bone or hypercalcemia of malignancy: loading dose of 120 billable units on days 1, 8, 15, and 29, followed by maintenance dosing of 120 billable units every 4 weeks.
    • Bone metastases from solid tumors or multiple myeloma: 120 billable units every 4 weeks.

    Universal Criteria for Xgeva and Other Oncology Indications

    Covered when ALL applicable criteria are met:

    ALL of the following

    • Member will receive calcium and vitamin D as necessary to treat or prevent hypocalcemia; this requirement does not apply when treatment is for hypercalcemia of malignancy.
    • Member does not have an FDA-labeled contraindication to the requested agent, including hypocalcemia or known clinically significant hypersensitivity to Xgeva or denosumab products.
    • Requested therapy will not be used in combination with another denosumab product, a bisphosphonate, romosozumab, or a parathyroid hormone analog or related peptide.

    Multiple Myeloma or Bone Metastases from Solid Tumors

    Covered when ALL applicable criteria are met:

    ALL of the following

    • Member is at least 18 years of age.
    • ONE of the following

      • Member has tried zoledronic acid for at least 3 months and had an inadequate response, contraindication, or intolerance.
      • Member has metastatic breast cancer, metastatic castration-resistant prostate cancer, or metastatic lung cancer, including small-cell or non-small-cell lung cancer.

    Giant Cell Tumor of Bone

    Covered when ALL applicable criteria are met:

    ALL of the following

    • Member is an adult or is at least 12 years of age and skeletally mature.
    • ONE of the following

      • Disease is unresectable or surgical resection is likely to result in severe morbidity.
      • ALL of the following

        • Disease is localized, recurrent, or metastatic.
        • ONE of the following

          • Denosumab is used as a single agent.

    Hypercalcemia of Malignancy

    Covered when ALL applicable criteria are met:

    ALL of the following

    • Member is at least 18 years of age.
    • Member has a diagnosis of cancer (malignancy).
    • ONE of the following

      • Refractory hypercalcemia of malignancy, defined as albumin-corrected calcium >12.5 mg/dL (3.1 mmol/L) despite a minimum 7-day trial of intravenous bisphosphonate therapy, such as ibandronate or zoledronic acid.
      • Documented contraindication or intolerance to intravenous bisphosphonates, such as ibandronate or zoledronic acid.

    Renewal Criteria

    Renewal requires ALL applicable criteria:

    ALL of the following

    • Member continues to meet universal and relevant indication-specific criteria identified in the initial approval criteria, including applicable concomitant therapy requirements, performance status, and other clinical requirements; prerequisite therapy requirements do not need to be repeated.
    • Member has no unacceptable toxicity from the drug, including severe symptomatic hypocalcemia, osteonecrosis of the jaw, atypical femoral fracture, dermatologic adverse reaction, severe infection, severe hypersensitivity or anaphylaxis, or musculoskeletal pain.
    • Beneficial response is demonstrated for the applicable indication

      • Systemic mastocytosis: improvement or resolution of bone pain compared with pretreatment baseline.
      • Systemic mastocytosis: absence of fractures.

    Osteoporosis Duration Management

    For osteoporosis in men and women, after 5 years of treatment, ALL of the following are required:

    ALL of the following

    • Member will have a repeat DXA performed after 5 years of treatment.
    • Member's fracture risk has been reassessed.
    • If disease risk is low to moderate, therapy will be changed to an oral or intravenous bisphosphonate unless the member has a contraindication or intolerance to both dosage forms.

    Glucocorticoid-Induced Osteoporosis Duration Management

    For glucocorticoid-induced osteoporosis, after 2 years of treatment, ALL of the following are required:

    ALL of the following

    • Member will have a repeat DXA performed after 2 years of treatment.
    • Member's fracture risk has been reassessed.
    • If disease risk is low to moderate, therapy will be changed to an oral or intravenous bisphosphonate unless the member has a contraindication or intolerance to both dosage forms.

    Coverage is not provided when the requested agent has an FDA-labeled contraindication, including hypocalcemia or known hypersensitivity. Hypocalcemia must be corrected before treatment when applicable. For oncology indications, calcium and vitamin D should be provided as necessary to treat or prevent hypocalcemia, except when the indication is hypercalcemia of malignancy.

    Coverage may be denied when required age, diagnosis, fracture-risk, prior-therapy, laboratory-monitoring, pregnancy-screening, response, or toxicity criteria are not documented or are not met.

    Members with advanced kidney disease, including dialysis-dependent members, require evaluation for CKD-mineral and bone disorder with intact parathyroid hormone, serum calcium, 25-hydroxy vitamin D, and 1,25-dihydroxy vitamin D before treatment decisions.

    Pregnancy must be ruled out before administration in biological females of child-bearing potential.

    Denosumab must not be used in combination with another denosumab product, bisphosphonates, romosozumab, or parathyroid hormone analogs or related peptides. Requests involving prohibited combination therapy are not covered.

    Initial Therapy Criteria

    Universal Initial Therapy

    Initial therapy requires all universal denosumab criteria:

    Universal initial therapy requirements: Member is at least 18 years of age; supplements with calcium 1,000 mg and vitamin D at least 400 IU daily; has no FDA-labeled contraindication; pregnancy is ruled out when applicable; and will not receive denosumab with another denosumab product, bisphosphonate, romosumab, or parathyroid hormone analog or related peptide.Age ≥18; calcium 1,000 mg/day; vitamin D ≥400 IU/day

    For advanced kidney disease, CKD-mineral and bone disorder laboratory monitoring is required before treatment decisions.

    Bisphosphonate Prerequisite

    For osteoporosis-related indications, initial therapy also requires one of the following:

    Bisphosphonate history or contraindication

    • Prior treatment failure:

    Continuation and Renewal Criteria

    Renewal Authorization

    Renewal may be requested after the initial authorization period:

    Renewal authorization: Prior authorization may be renewed every 12 months (365 days).12 months (365 days)

    Additional clinical continuation criteria apply to the renewal review.

    Denosumab Renewal

    Renewal requires all of the following:

    Denosumab renewal: Member continues to meet relevant universal and indication-specific criteria; has no unacceptable toxicity; and demonstrates the required beneficial response for the treated indication.

    Osteoporosis requires repeat DXA and fracture-risk reassessment after 5 years; glucocorticoid-induced osteoporosis requires these assessments after 2 years.

    Step Therapy Requirements

    StepPreferred productsRequirement
    1Bildyos and EnobyUse the preferred denosumab products before other listed products. A contraindication, intolerance, or failure of both Bildyos and Enoby must be documented for nonpreferred products.
    StepTherapy prerequisiteRequirement or exception
    2Oral or intravenous bisphosphonateDocument treatment failure or an ineffective response to at least 12 months of bisphosphonate therapy, or a contraindication or intolerance to both oral and intravenous bisphosphonates. Members at very high fracture risk are exempt from the prior trial-and-failure requirement.
    StepPreferred productsRequirement
    1Bilprevda and XtrenboUse the preferred denosumab products before nonpreferred denosumab products. A contraindication, intolerance, or failure of both Bilprevda and Xtrenbo must be documented for nonpreferred products.
    StepTherapy prerequisiteRequirement or exception
    1Zoledronic acidFor multiple myeloma or bone metastases from solid tumors, document an inadequate response, contraindication, or intolerance to at least a 3-month trial of zoledronic acid. The prerequisite does not apply when the member has metastatic breast cancer, metastatic castration-resistant prostate cancer, or metastatic lung cancer, including SCLC or NSCLC.
    StepTherapy prerequisiteRequirement or exception
    1Intravenous bisphosphonateFor hypercalcemia of malignancy, document refractory disease after at least a 7-day trial of an intravenous bisphosphonate such as ibandronate or zoledronic acid, or a documented contraindication or intolerance to these agents.

    Quantity Limits and Administration

    Quantity limit
    ProductsProlia, Bildyos, Boncresa, Bosaya, Conexxence, Denosumab-adet, Denosumab-dssb, Enoby, Jubbonti, Ospomyv, Osvyrti, Ponlimsi, and Stoboclo
    Quantity limit60 billable units
    FrequencyEvery 6 months
    Quantity limit
    IndicationsOsteoporosis and systemic mastocytosis
    Quantity limit60 billable units
    FrequencyEvery 6 months

    Coding and Diagnosis Codes

    Covered HCPCS CodesHCPCSCovered
    J0897Injection, denosumab, 1 mg; 1 billable unit = 1 mg
    Covered HCPCS CodesHCPCSCovered
    Q5136Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg; 1 billable unit = 1 mg
    Covered HCPCS CodesHCPCSCovered
    Q5157Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg; 1 billable unit = 1 mg
    Neutral HCPCS CodesHCPCS
    Q5136Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg; 1 billable unit = 1 mg
    Neutral HCPCS CodesHCPCS
    Q5157Injection, denosumab-bmwo (stoboclo/osenvelt), biosimilar, 1 mg; 1 billable unit = 1 mg
    Neutral HCPCS CodesHCPCS
    Q5158Injection, denosumab-bnht (bomyntra/conexxence), biosimilar, 1 mg; 1 billable unit = 1 mg
    Neutral HCPCS CodesHCPCS
    Q5159Injection, denosumab-dssb (ospomyv/xbryk), biosimilar, 1 mg; 1 billable unit = 1 mg
    Neutral HCPCS CodesHCPCS
    Q5161Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg; 1 billable unit = 1 mg
    Neutral HCPCS CodesHCPCS
    Q5162Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg; 1 billable unit = 1 mg
    Neutral HCPCS CodesHCPCS
    Q5167Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg; 1 billable unit = 1 mg
    Q5166Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg; 1 billable unit = 1 mg
    Neutral HCPCS CodesHCPCS
    Q5171Injection, denosumab-mobz (boncresa), biosimilar, 1 mg; 1 billable unit = 1 mg
    Q5165Injection, denosumab-mobz (oziltus), biosimilar, 1 mg; 1 billable unit = 1 mg
    Neutral HCPCS CodesHCPCS
    J3590Unclassified biologics (Discontinue use on 10/01/2026)
    Q5173Injection, denosumab-adet (ponlimsi), biosimilar, 1 mg; 1 billable unit = 1 mg (Effective 10/01/2026)
    Neutral NDC CodesNDC
    55513-0710-xxProlia 60 mg/1 mL single-dose prefilled syringe
    61314-0240-xxJubbonti 60 mg/1 mL single-dose prefilled syringe
    83457-0012-xxOspomyv 60 mg/1 mL single-dose prefilled syringe
    71202-0013-xxDenosumab-dssb 60 mg/1 mL single-dose prefilled syringe
    72606-0037-xxStoboclo 60 mg/1 mL single-dose prefilled syringe
    72606-0058-xxDenosumab-bmwo 60 mg/1 mL single-dose prefilled syringe
    65219-0668-xxConexxence 60 mg/1 mL single-dose prefilled syringe
    65219-0680-xxDenosumab-bnht 60 mg/1 mL single-dose prefilled syringe
    78206-0193-xxBildyos 60 mg/1 mL single-dose prefilled syringe
    78206-0194-xxBildyos 60 mg/1 mL single-dose vial
    1–10 of 19
    1/2
    Neutral NDC CodesNDC
    72606-0038-xxOsenvelt 120 mg/1.7 mL single-dose vial
    72606-0059-xxDenosumab-bmwo 120 mg/1.7 mL single-dose vial
    65219-0670-xxBomyntra 120 mg/1.7 mL single-dose vial
    65219-0672-xxBomyntra 120 mg/1.7 mL single-dose prefilled syringe
    65219-0682-xxDenosumab-bnht 120 mg/1.7 mL single-dose vial
    65219-0684-xxDenosumab-bnht 120 mg/1.7 mL single-dose prefilled syringe
    83257-0030-xxAukelso 120 mg/1.7 mL single-dose vial
    78206-0195-xxBilprevda 120 mg/1.7 mL single-dose vial
    00143-9166-xxXtrenbo 120 mg/1.7 mL single-dose vial
    69448-0022-xxJubereq 120 mg/1.7 mL single-dose vial
    1–10 of 11
    1/2
    Covered Diagnosis CodesICD-10Covered
    C50.011-C50.929Malignant neoplasms of breast
    C50.A0-C50.A2Malignant inflammatory neoplasm of breast
    C61Malignant neoplasm of prostate
    C94.30Mast cell leukemia not having achieved remission
    C94.31Mast cell leukemia, in remission
    C94.32Mast cell leukemia, in relapse
    C96.20Malignant mast cell neoplasm, unspecified
    C96.21Aggressive systemic mastocytosis
    C96.22Mast cell sarcoma
    C96.29Other malignant mast cell neoplasm
    1–10 of 37
    1/4
    Covered Diagnosis CodesICD-10Covered
    C00-C14Malignant neoplasms of lip, oral cavity and pharynx
    C15-C26Malignant neoplasms of digestive organs
    C30-C39Malignant neoplasms of respiratory and intrathoracic organs
    C40-C41Malignant neoplasms of bone and articular cartilage
    C43-C44Melanoma and other malignant neoplasms of skin
    C45-C49Malignant neoplasms of mesothelial and soft tissue
    C50.011-C50.929Malignant neoplasms of breast
    C50.A0-C50.A2Malignant inflammatory neoplasm of breast
    C51-C58Malignant neoplasms of female genital organs
    C60-C63Malignant neoplasms of male genital organs
    1–10 of 48
    1/5
    Prolia and listed osteoporosis-product dose
    ProductsProlia and listed osteoporosis products
    Dose60 billable units
    FrequencyEvery 6 months
    Loading dose

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Denosumab products require prior authorization, with review by a pharmacist before approval.

    • Applies to requested denosumab products covered under this policy.
    Billing Rule

    Authorization Duration

    Initial authorization is valid for 12 months (365 days). Renewal authorization may be granted for additional 12-month (365-day) periods when renewal criteria are met.

    • Initial: 12 months (365 days)
    • Renewal: every 12 months (365 days)

    Administration Site

    Billing Rule

    Administer in the appropriate site of care

    Denosumab is administered subcutaneously by a health care provider in the office setting.

    Preferred and Biosimilar Products

    Step Therapy

    Bildyos preferred product

    Bildyos is a preferred denosumab product. Nonpreferred listed products require contraindication, intolerance, or failure of Bildyos and Enoby.

    Step Therapy

    Enoby preferred product

    Enoby is a preferred denosumab product. Nonpreferred listed products require contraindication, intolerance, or failure of Bildyos and Enoby.

    Step Therapy

    Bilprevda preferred product

    Bilprevda is a preferred denosumab product. Nonpreferred products require contraindication, intolerance, or failure of Bilprevda and Xtrenbo.

    Policy Definitions

    Ineffective response
    DXA criterionDecrease in T-score compared with the baseline DXA scan
    Fracture criterionNew fracture while receiving bisphosphonate therapy
    DefinitionEither criterion constitutes an ineffective response
    High risk for fracture
    Fracture historyHistory of an adult osteoporotic fracture or parental history of hip fracture
    Clinical factorsLow BMI, rheumatoid arthritis, current smoking, or alcohol intake of 3 or more drinks per day
    Glucocorticoid history

    Clinical Background

    Denosumab is covered under this policy for conditions involving bone loss and skeletal complications, including osteoporosis, glucocorticoid-related osteoporosis, systemic mastocytosis, and cancer-related conditions. Cancer-related uses include bone metastases from solid tumors, multiple myeloma, giant cell tumor of bone, and hypercalcemia of malignancy; additional bone-mass indications include prostate cancer during androgen-deprivation therapy and breast cancer during adjuvant aromatase-inhibitor therapy. Dosing varies by indication, from 60 billable units every 6 months for osteoporosis and systemic mastocytosis to 120 billable units every 4 weeks for bone metastases and multiple myeloma, with loading doses used for giant cell tumor of bone and hypercalcemia of malignancy.

    Policy Summary
    PayerHealth Plan of the Upper Ohio Valley, Inc.
    PolicyDenosumab Prior Authorization Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit denosumab requests for prior authorization and pharmacist review.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation and Renewal CriteriaStep Therapy RequirementsQuantity Limits and AdministrationCoding and Diagnosis CodesAuthorization and Documentation RequirementsAdministration SitePreferred and Biosimilar ProductsPolicy DefinitionsClinical Background
    DXA T-score is between -1.0 and -2.5 at the lumbar spine, femoral neck, total hip, or forearm at the 33% (one-third) radius site.
  1. ONE of the following

    • History of fracture of the proximal humerus, pelvis, or distal forearm.
    • FRAX 10-year probability for major fracture is ≥20% or hip fracture is ≥3%.
  2. ONE of the following

    • Documented treatment failure or ineffective response to a minimum 12-month trial of an oral or intravenous bisphosphonate, such as alendronate, risedronate, ibandronate, or zoledronic acid.
    • Documented contraindication or intolerance to both oral and intravenous bisphosphonates.
  3. Denosumab is used in combination with serial embolization and/or radiation therapy.
  4. Systemic mastocytosis: increase in bone mineral density compared with pretreatment baseline.
  5. All other osteoporosis-related indications: absence of fractures.
  6. All other osteoporosis-related indications: increase in bone mineral density compared with pretreatment baseline.
  7. Multiple myeloma or bone metastases from solid tumors: absence or delay in skeletal-related events, such as pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression.
  8. Giant cell tumor of bone: stabilization of disease or decrease in tumor size or spread.
  9. Hypercalcemia of malignancy: corrected serum calcium ≤11.5 mg/dL (2.9 mmol/L).
  10. Documented treatment failure or ineffective response to a minimum 12-month trial of oral or IV bisphosphonate therapy.
    Minimum 12 months
  11. Contraindication or intolerance: Documented contraindication or intolerance to both oral and IV bisphosphonates.
  12. Multiple Myeloma or Solid-Tumor Bone Metastases

    For prevention of skeletal-related events, all of the following must be met:

    Multiple myeloma or solid-tumor bone metastases

    • Prerequisite therapy or specified metastatic cancer

      • Zoledronic acid pathway: Member has an inadequate response, contraindication, or intolerance to at least a 3-month trial of zoledronic acid.At least 3 months
      • Specified metastatic cancer: Member has metastatic breast cancer, metastatic castration-resistant prostate cancer, or metastatic lung cancer, including SCLC or NSCLC.

    Giant Cell Tumor of Bone

    For giant cell tumor of bone, all of the following must be met:

    Giant cell tumor of bone: Member is an adult or at least 12 years old and skeletally mature; disease is unresectable, likely to require resection causing severe morbidity, localized, recurrent, or metastatic; and treatment is used as a single agent or in combination with serial embolization and/or radiation therapy.Age ≥12 years and skeletally mature when applicable

    Hypercalcemia of Malignancy

    For hypercalcemia of malignancy, all of the following must be met:

    Hypercalcemia of malignancy: Member is at least 18 years old, has cancer or malignancy, and has either refractory hypercalcemia after at least 7 days of prior IV bisphosphonate therapy or a documented contraindication or intolerance to IV bisphosphonates.Age ≥18 years; calcium >12.5 mg/dL for refractory disease; prior trial ≥7 days

    Prior IV bisphosphonates include ibandronate or zoledronic acid.

    Quantity limit
    IndicationsGiant cell tumor of bone or hypercalcemia of malignancy
    Loading dose120 billable units on Days 1, 8, 15, and 29
    Maintenance dose120 billable units every 4 weeks
    Quantity limit
    IndicationsBone metastases from solid tumors or multiple myeloma
    Quantity limit120 billable units
    FrequencyEvery 4 weeks
    Administration
    ProductsProlia and listed 60 mg denosumab products
    Dose60 mg subcutaneously
    AdministrationAdministered by a health care provider every 6 months
    Administration
    ProductsXgeva and listed 120 mg denosumab products
    Dose120 mg subcutaneously
    FrequencyEvery 4 weeks
    Initial additional doses
    ProductsXgeva and listed 120 mg denosumab products
    Additional doses120 mg on Days 8 and 15 of the first month of therapy
    Base schedule120 mg subcutaneously every 4 weeks
    IndicationsGiant cell tumor of bone and hypercalcemia of malignancy
    Dose120 billable units
    Loading scheduleDays 1, 8, 15, and 29
    Maintenance dose
    IndicationsGiant cell tumor of bone and hypercalcemia of malignancy
    Dose120 billable units
    FrequencyEvery 4 weeks after loading
    Dose
    IndicationsBone metastases from solid tumors and multiple myeloma
    Dose120 billable units
    FrequencyEvery 4 weeks
    Osteoporosis DXA threshold
    Qualifying T-score≤ -2.5
    Measurement sitesLumbar spine, femoral neck, total hip, or forearm at the 33% (one-third) radius site
    Assessment methodDXA measurement
    Intermediate DXA and fracture-risk threshold
    T-score rangeBetween -1.0 and -2.5
    Fracture criterionFracture of the proximal humerus, pelvis, or distal forearm
    FRAX criterion10-year probability of major fracture ≥20% or hip fracture ≥3%
    Glucocorticoid exposure
    MedicationPrednisone or equivalent glucocorticoid
    Daily doseAt least 2.5 mg prednisone equivalent
    Expected durationAt least 3 months
    Bisphosphonate renal contraindication
    TherapyOral or injectable bisphosphonate therapy
    Contraindication thresholdCreatinine clearance <30-35 mL/min
    Clinical contextDocumented pre-existing renal insufficiency may contraindicate bisphosphonate therapy
    High-dose glucocorticoid exposure
    MedicationPrednisone or equivalent
    Daily threshold≥30 mg/day for more than 30 days
    Annual threshold≥5 g/year
    Glucocorticoid-adjusted FRAX threshold
    Major osteoporotic fracture risk≥20% over 10 years
    Hip fracture risk≥3% over 10 years
    Risk toolGlucocorticoid-adjusted FRAX
    Refractory hypercalcemia of malignancy
    Corrected calciumAlbumin-corrected calcium >12.5 mg/dL (3.1 mmol/L)
    Prior treatmentAt least a 7-day trial of intravenous bisphosphonate therapy
    Examples of prior therapyIbandronate or zoledronic acid
    Renewal response for hypercalcemia
    ConditionHypercalcemia of malignancy
    Response thresholdCorrected serum calcium ≤11.5 mg/dL (2.9 mmol/L)
    UseBeneficial disease response for renewal
    Prior Authorization

    Denosumab Product Authorization

    Prior authorization applies to Prolia, Bildyos, Boncresa, Bosaya, Conexxence/denosumab-bnht, Enoby, Jubbonti, Ospomyv/denosumab-dssb, Osvyrti, Ponlimsi/denosumab-adet, and Stoboclo/denosumab-bmwo. Preferred-product requirements apply to this product group.

    • Preferred products: Bildyos and Enoby
    • The requested product must meet the applicable indication-specific criteria.
    Note

    Prior Authorization Factors

    Prior authorization is based on clinically relevant utilization-management factors, including the indication, safety and efficacy, and drug cost. Potential for misuse or abuse was not identified as a priority factor for this policy.

    • Indication: considered for prior authorization
    • Safety and efficacy: considered for prior authorization
    • Cost: considered for prior authorization
    • Potential for misuse/abuse: not a prior-authorization priority
    Step Therapy

    Preferred Denosumab Step

    For the Prolia/Bildyos/Enoby product group, Bildyos and Enoby are preferred. The member must have a documented contraindication, intolerance, or treatment failure with both preferred products before a nonpreferred denosumab product is authorized.

    • Preferred products: Bildyos and Enoby
    • Document the contraindication, intolerance, or failure for each applicable preferred product.

    Unsupported block type: step_therapy

    Step Therapy

    Zoledronic Acid Prerequisite

    For prevention of skeletal-related events in multiple myeloma or bone metastases from solid tumors, the member must generally have tried zoledronic acid for at least 3 months and had an inadequate response, or have a documented contraindication or intolerance.

    • Exception: metastatic breast cancer, metastatic castration-resistant prostate cancer, or metastatic lung cancer may satisfy the indication-specific pathway.
    • Document the zoledronic acid trial and outcome, or the contraindication/intolerance.

    Unsupported block type: step_therapy

    Unsupported block type: step_therapy

    Documentation Required

    Universal Safety Documentation

    Document calcium and vitamin D supplementation and screen for FDA-labeled contraindications before administration. Pregnancy must be ruled out before administration in biologic females of child-bearing potential.

    • For osteoporosis-related use: calcium 1,000 mg and at least 400 IU of vitamin D daily.
    • For other denosumab use: provide calcium and vitamin D as necessary to treat or prevent hypocalcemia; supplementation excludes use for hypercalcemia of malignancy.
    • Do not use when the requested agent is contraindicated, including hypocalcemia or known clinically significant hypersensitivity.
    Documentation Required

    Advanced Kidney Disease Monitoring

    For members with advanced kidney disease, defined as eGFR <30 mL/min/1.73 m² or dialysis dependence, document monitoring for chronic kidney disease–mineral and bone disorder before decisions regarding denosumab treatment.

    • Obtain and document intact parathyroid hormone (iPTH).
    • Document serum calcium, 25(OH) vitamin D, and 1,25(OH)₂ vitamin D.
    Documentation Required

    Clinical Supporting Documentation

    Submit clinical documentation supporting the qualifying diagnosis, disease severity or fracture risk, relevant testing, prior treatment, and response to therapy.

    • Osteoporosis: diagnosis supported by DXA T-score criteria, qualifying fragility fracture, or osteopenia with qualifying fracture or FRAX risk; document high fracture risk.
    • Glucocorticoid-induced osteoporosis: document glucocorticoid dose and expected duration, increased fracture risk, and supporting DXA, fracture, or FRAX findings.
    • Systemic mastocytosis: document osteopenia or osteoporosis with coexisting bone pain and the rationale for second-line or renal-related use.
    • Document prior bisphosphonate treatment, failure or ineffective response, or contraindication/intolerance when required.
    • Document ineffective response, including a decrease in DXA T-score from baseline or a new fracture during bisphosphonate therapy.
    Documentation Required

    Diagnosis and Prerequisite-Treatment Documentation

    For cancer-related indications, giant cell tumor of bone, and hypercalcemia of malignancy, document the qualifying diagnosis, disease status, age and eligibility requirements, and prerequisite treatment history when applicable.

    • Multiple myeloma or solid-tumor bone metastases: document diagnosis, age ≥18, and zoledronic acid trial with inadequate response, contraindication, or intolerance, unless the specified metastatic-cancer exception applies.
    • Giant cell tumor of bone: document adult or age ≥12 and skeletally mature status, plus unresectable disease, likely severe morbidity from resection, or localized/recurrent/metastatic disease.
    • Hypercalcemia of malignancy: document age ≥18, malignancy, corrected calcium >12.5 mg/dL despite at least 7 days of IV bisphosphonate therapy, or IV bisphosphonate contraindication/intolerance.
    Documentation Required

    Renewal Documentation

    Renewal requests must document continued universal and indication-specific criteria, absence of unacceptable toxicity, and beneficial clinical response with updated findings appropriate to the indication.

    • Continue to document required concomitant therapy and other indication-specific criteria.
    • For systemic mastocytosis: document improved or resolved bone pain, absence of fractures, or increased bone mineral density.
    • For other osteoporosis indications: document absence of fractures or increased bone mineral density.
    • For multiple myeloma or solid-tumor bone metastases: document absence or delay of skeletal-related events.
    • For giant cell tumor: document disease stabilization or decreased tumor size or spread.
    • For hypercalcemia of malignancy: document corrected serum calcium ≤11.5 mg/dL (2.9 mmol/L).
    • Include repeat DXA and fracture-risk reassessment when required by treatment duration.
    Denial Risk

    Preferred-Product Requirement

    Nonpreferred denosumab products may be denied when the applicable preferred products have not been tried and failed, or when a contraindication or intolerance to the preferred products has not been documented.

    • Prolia-related product group: Bildyos and Enoby are preferred.
    • Cancer-related product group: Bilprevda and Xtrenbo are preferred.
    Denial Risk

    Contraindication or Prohibited Combination

    Denosumab is not authorized when the requested agent has an FDA-labeled contraindication or when prohibited combination therapy is planned.

    • Contraindications include hypocalcemia and known or clinically significant hypersensitivity to the requested agent.
    • Do not combine with another denosumab product, a bisphosphonate, romosozumab, or a parathyroid hormone analog or related peptide.
    • For biologic females of child-bearing potential, pregnancy must be ruled out before administration.
    Denial Risk

    Bisphosphonate Prerequisite

    When a bisphosphonate prerequisite applies, authorization may be denied without documentation of treatment failure or ineffective response, or a contraindication or intolerance to the required oral and IV options.

    • For osteoporosis and glucocorticoid-induced osteoporosis, document the required minimum 12-month oral or IV bisphosphonate trial unless the member is very high risk or cannot use both forms.
    • For systemic mastocytosis, document failure to respond to bisphosphonate therapy or renal insufficiency preventing bisphosphonate use.
    • Ineffective response includes a lower DXA T-score from baseline or a new fracture while receiving bisphosphonate therapy.
    Step Therapy

    Preferred-Product Requirement

    For the Xgeva-related product group, Bilprevda and Xtrenbo are the preferred denosumab products. A nonpreferred product requires documented contraindication, intolerance, or failure of both preferred products.

    • Preferred products: Bilprevda and Xtrenbo.
    Denial Risk

    FDA Contraindication

    Do not authorize denosumab when hypocalcemia or clinically significant hypersensitivity to the requested agent is present.

    • Screen for FDA-labeled contraindications before administration.
    • Document correction or resolution of hypocalcemia when clinically appropriate.
    Denial Risk

    Prohibited Combination Therapy

    Denosumab must not be used in combination with another denosumab product, bisphosphonates, romosozumab, or parathyroid hormone analogs or related peptides.

    • Review the complete medication regimen before authorization and administration.
    Denial Risk

    Unacceptable Toxicity

    Renewal may be denied when unacceptable toxicity is present or not adequately addressed. Examples include severe symptomatic hypocalcemia, osteonecrosis of the jaw, atypical femoral fractures, dermatologic adverse reactions, severe infection, severe hypersensitivity or anaphylaxis, and significant musculoskeletal pain.

    • Document toxicity assessment and management with each renewal request.
    Denial Risk

    Insufficient Clinical Response

    Renewal requires evidence of beneficial disease response appropriate to the indication; insufficient response may result in denial.

    • Systemic mastocytosis: improved or resolved bone pain, no fractures, or increased bone mineral density.
    • Other osteoporosis indications: no fractures or increased bone mineral density compared with baseline.
    • Multiple myeloma or solid-tumor bone metastases: absence or delay of skeletal-related events, such as pathologic fracture, radiation or surgery to bone, or spinal cord compression.
    • Giant cell tumor of bone: disease stabilization or decreased tumor size or spread.
    • Hypercalcemia of malignancy: corrected serum calcium ≤11.5 mg/dL (2.9 mmol/L).
    • Include objective follow-up findings, such as repeat DXA or laboratory results, when applicable.
    Step Therapy

    Xtrenbo preferred product

    Xtrenbo is a preferred denosumab product. Nonpreferred products require contraindication, intolerance, or failure of Bilprevda and Xtrenbo.

    Billing Rule

    Jubbonti biosimilar listing

    Jubbonti is listed as a denosumab-bbdz biosimilar to Prolia.

    Billing Rule

    Wyost biosimilar listing

    Wyost is listed as a denosumab-bbdz biosimilar to Prolia.

    Billing Rule

    Ospomyv biosimilar listing

    Ospomyv is listed as a denosumab-dssb biosimilar for Prolia or Xgeva, as applicable to the 60 mg or 120 mg presentation.

    Billing Rule

    Stoboclo biosimilar listing

    Stoboclo is listed as a denosumab-bmwo biosimilar for Prolia or Xgeva, as applicable to the 60 mg or 120 mg presentation.

    Billing Rule

    Conexxence biosimilar listing

    Conexxence is listed as a denosumab-bnht biosimilar for Prolia or Xgeva, as applicable to the 60 mg or 120 mg presentation.

    Billing Rule

    Enoby biosimilar listing

    Enoby is listed as a denosumab-qbde biosimilar for Prolia or Xgeva, as applicable to the 60 mg or 120 mg presentation.

    Billing Rule

    Bosaya biosimilar listing

    Bosaya is listed as a denosumab-kyqq biosimilar for Prolia or Xgeva, as applicable to the 60 mg or 120 mg presentation.

    Billing Rule

    Bildyos biosimilar listing

    Bildyos is listed as a denosumab-nxxp biosimilar for Prolia or Xgeva, as applicable to the 60 mg or 120 mg presentation.

    Billing Rule

    Osvyrti biosimilar listing

    Osvyrti is listed as a denosumab-desu biosimilar for Prolia or Xgeva, as applicable to the 60 mg or 120 mg presentation.

    Billing Rule

    Boncresa biosimilar listing

    Boncresa is listed as a denosumab-mobz biosimilar for Prolia or Xgeva, as applicable to the 60 mg or 120 mg presentation.

    Billing Rule

    Ponlimsi biosimilar and code update

    Ponlimsi is listed as a denosumab-adet biosimilar for Prolia or Xgeva, as applicable to the 60 mg or 120 mg presentation. Q5173 is effective 10/01/2026; J3590 is discontinued for use on that date.

    Oral glucocorticoids ≥5 mg/day of prednisone or equivalent for more than 3 months
    Very high fracture risk
    Recent or treatment-associated fractureRecent fracture within 12 months, fracture while on osteoporosis therapy, or fracture while taking drugs causing skeletal harm
    Fracture burdenMultiple fractures
    Additional factorsT-score < -3.0, very high FRAX fracture probability, high fall risk, or history of injurious falls
    Increased glucocorticoid-induced osteoporosis fracture risk
    Prior fracturePrior osteoporotic fracture
    Glucocorticoid exposureHigh-dose use: prednisone or equivalent ≥30 mg/day for more than 30 days or ≥5 g/year
    FRAX or DXAGlucocorticoid-adjusted FRAX major fracture risk ≥20% or hip risk ≥3%, or DXA T-score < -2.5 at specified sites
    Refractory hypercalcemia of malignancy
    Calcium thresholdAlbumin-corrected calcium >12.5 mg/dL (3.1 mmol/L)
    Prior therapyCondition persists despite a minimum 7-day trial of IV bisphosphonate therapy
    ExamplesIbandronate or zoledronic acid
    Skeletal-related event
    Pathologic fracturePathologic fracture
    Bone treatmentRadiation therapy to bone or surgery to bone
    Spinal complicationSpinal cord compression
    Skeletally mature
    Minimum ageAt least 12 years old
    Skeletal requirementMust be skeletally mature
    Applicable conditionQualifying adolescent with giant cell tumor of bone